Collaborations - Additional Information (Details) $ / shares in Units, $ in Thousands								1 Months Ended	12 Months Ended
	Jul. 06, 2021 USD ($) $ / shares shares	Aug. 25, 2020 USD ($) $ / shares shares	Aug. 20, 2020	Jul. 07, 2020 USD ($)	May 09, 2019 USD ($) $ / shares shares	Nov. 01, 2018	Oct. 31, 2017 shares	Jul. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($) shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cost reimbursement payment received									$ 6,700	$ 4,800
Unbilled accounts receivable									$ 2,500	100
Remaining research term of collaboration									3 years
Aggregate proceeds from issuance of private placement									$ 174
Revenue recognized									46,826	72,832	$ 34,034
Reverse stock split			1.5949
Research and development									$ 164,248	137,017	62,105
Collaboration termination date									Apr. 27, 2022
Private Placement | Vertex Pharmaceuticals Incorporated
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of shares, Shares | shares	49,928	676,354
Common stock per share | $ / shares	$ 47.00	$ 20.00
Aggregate proceeds from issuance of private placement	$ 2,300	$ 13,500						$ 2,300
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment				$ 150,000
Collaboration agreement transaction price				150,000
Revenue recognized recorded in deferred revenue									$ 36,000	30,500	18,800
Unsatisfied performance obligation									54,900	81,800
Revenue recognized									36,000	54,300
Sanofi Agreement | Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price				120,000
Revenue recognized recorded in deferred revenue									19,400		16,700
Revenue recognized										45,500
Sanofi Agreement | Collaboration Target 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price				30,000
Revenue recognized recorded in deferred revenue									16,600		2,100
Revenue recognized										8,800
Sanofi Agreement | Minimum | IRAK4 Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments				1,000,000
Commercial milestone payments				400,000
Sanofi Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments				1,480,000
Commercial milestone payments				$ 700,000
Vertex Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized recorded in deferred revenue									10,800
Unsatisfied performance obligation									8,400	19,200
Initial research term of collaboration					4 years
Extended research term of collaboration					1 year
Revenue recognized									$ 10,800	$ 18,500	15,200
Vertex Agreement | Series B-1 Convertible Preferred
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price					$ 55,900
Non refundable upfront payment received					$ 50,000
Issuance of shares, Shares | shares					3,059,695
Common stock per share | $ / shares					$ 6.54
Preferred stock premium					$ 5,900
Vertex Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive payments including development, regulatory and commercial milestones					$ 170,000
Revenue remaining research term									6 months
Compound Collaboration | Series A Preferred Units
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of shares, Shares | shares							886,305
Reverse stock split						100
Share-based compensation vesting period						3 years
Research and development											$ 300
Vesting of Series A Preferred Stock in connection with collaboration arrangement (Note 5), Shares | shares											166,183